0
0
European Medicines Agency clears the way for Novavax vaccine to be approved in the EU.
The Amsterdam-based European Medicines Agency (EMA) recommended on Monday that the Corona vaccine from U.S. manufacturer Novavax be approved in the European Union. The responsible EMA committee recommended a conditional approval for 18-year-olds and older. All that is now missing is the approval of the EU Commission, but this is considered a mere formality. As Novavax has already announced in advance, the first shipments of the vaccine are expected to arrive in Europe as early as January.
The vaccine contains tiny particles consisting of a laboratory-produced version of the spike protein of Sars-CoV-2.
The vaccine is also repeatedly referred to as a “dead vaccine,” but according to Austrian virologist Florian Krammer, this is not entirely accurate. According to him, it is a recombinant protein vaccine.
4 vaccines approved
So far, 4 vaccines have been approved in the EU. The Novavax preparation could now possibly persuade some non-vaccinated people, who have doubts about the mode of action of the other active substances, to vaccinate after all. This is because, unlike the previously approved vaccines, the preparation is neither an mRNA vaccine – like the preparations from Biontech and Moderna – nor a vector vaccine, like those from AstraZeneca and Johnson & Johnson.
— source: futurezone.at/picture: pixabay.com
This post has already been read 768 times!
